Carter, M J
Cox, K L
Blakemore, S J
Turaj, A H
Oldham, R J
Dahal, L N
Tannheimer, S
Forconi, F
Packham, G
Cragg, M S
Article History
Received: 19 August 2016
Accepted: 21 October 2016
First Online: 15 November 2016
Competing interests
: MSC serves as a consultant for Bioinvent International and has previously served as an ad hoc consultant for Roche and Baxalta. He has previously received grant funding from Bioinvent, Roche, Gilead and GSK. GP receives research funding from Aquinox Pharmaceuticals and is a founder and shareholder in Karus Therapeutics.